Global recruitment of CMO/Senior Director for Clinical Study

1.Qualification and Requirements

1. MD or PhD on oncology/immunology/another relevant field.
2. 5+ years clinical experience in cancer treatment, especially hemooncology and myeloma.
3. 5+ years experience in clinical studies management for oncology or cell therapy.
4. 5+ years experience in big pharma senior management working on clinical development and medical affairs.

2.Roles and Responsibilities

1. Lead a team in designing the clinical development strategy or plan for cancer therapeutics.
2. Work with local development and project teams at headquarters to run the development of local cancer therapeutics in Latam.
3. Oversee and manage medical and clinical operations, ensuring compliance with regulatory standards and ethical practices in Latam. Work together with the RA team to get marketing authorization in Latam for cancer therapeutics products.
4. Develop and implement comprehensive policies and procedures related to medical care tailored to meet the company’s needs, working with partners, hospitals, and medical organization in Latam;
5. Collaborate with other departments in the company, providing medical advice and consultation to executives and stakeholders.
6. Foster a culture of continuous quality improvement, monitoring key performance indicators and implementing initiatives to optimize healthcare delivery.
7. Lead interdisciplinary teams, encouraging collaboration, communication and knowledge sharing among medical professionals and staff.
8. Build and maintain strong relationships with key stakeholders, including medical associations, government bodies and community organizations, to promote healthcare initiatives and partnerships.

 

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a Chinese biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines and antibodies. SINOVAC also produces other preventive and therapeutic products that protect against human infectious diseases.

SINOVAC is dedicated to addressing major challenges in disease prevention and treatment through cutting-edge technology. We focus on unmet medical needs regarding infectious disease and other significant therapeutic areas. All our work integrates cutting-edge research and major findings from across the world, concentrating strengths to develop first-in-class biopharmaceuticals such as vaccines, antibodies, and fusion proteins, ensuring high-quality products reach the market swiftly. Our high R&D standards are backed by innovation-driven platforms such as the United Research Institute of SINOVAC (URIS) for drug discovery and our product-oriented CMC platform. We also run clinical demand support platforms such as our Analysis Center and Animal Center for Drug Evaluation. Our world-class facilities mean we have a mature system for developing preventive and therapeutic products, with multiple types of technologies including our own core technologies. Our multidisciplinary research team, covering fields such as pharmacy, biology, medicine, and chemistry, are at the forefront of global research and innovation.

Going forward, SINOVAC will promote both the research and industrialization of biopharmaceuticals. While continuing to develop its vaccine industry, we will also expand our markets in therapeutic monoclonal antibodies, gene therapy, and cell therapy. Through independent R&D, collaboration, and external investment, we will accelerate the industrialization of high-quality biopharmaceuticals to fulfil global disease prevention and control, improving global health and well-being.

Since being founded in 2001, our mission has been to “supply vaccines to eliminate human diseases”. SINOVAC has developed a comprehensive portfolio including vaccines against common infectious diseases like hepatitis virus, seasonal influenza, pneumococcal disease, poliomyelitis, varicella, and mumps, as well as emerging ones, such as COVID-19, enterovirus71 (EV71) related Hand-Foot-Mouth disease (HFMD), H5N1 influenza (avian flu), H1N1 influenza (swine flu) and SARS.

Thanks to its comprehensive quality management, SINOVAC has four vaccines approved by the World Health Organization (WHO). Its hepatitis A vaccine Healive®, Sabin-strain inactivated poliomyelitis vaccine (sIPV), and varicella vaccine were granted WHO prequalification (“PQ”); and its COVID-19 vaccine CoronaVac® was validated by the WHO under the Emergency Use Listing (“EUL”) Procedure.